Background. A number of cerebral manifestations are associated with JC polyomavirus (JCPyV) which are diagnosed by detection of JCPyV in cerebrospinal fluid (CSF), often with the support of cerebral imaging. Here we present an unusual case of a kidney transplant patient presenting with progressive neurological deterioration attributed to JCPyV encephalopathy. Methods. Quantitative polymerase chain reaction JCPyV was used prospectively and retrospectively to track the viral load within the patient blood, urine, CSF, and kidney sections. A JCPyV VP1 enzyme-linked immunosorbent assay was used to measure patient and donor antibody titers. Immunohistochemical staining was used to identify active JCPyV infection within the kidney allograft. Results. JC polyomavirus was detected in the CSF at the time of presentation. JC polyomavirus was not detected in pretransplant serum, however viral loads increased with time, peaking during the height of the neurological symptoms (1.5E 9 copies/mL). No parenchymal brain lesions were evident on imaging, but transient cerebral venous sinus thrombosis was present. Progressive decline in neurological function necessitated immunotherapy cessation and allograft removal, which led to decreasing serum viral loads and resolution of neurological symptoms. JC polyomavirus was detected within the graft's collecting duct cells using quantitative polymerase chain reaction and immunohistochemical staining. The patient was JCPyV naive pretransplant, but showed high antibody titers during the neurological symptoms, with the IgM decrease paralleling the viral load after graft removal. Conclusions. We report a case of atypical JCPyV encephalopathy associated with cerebral venous sinus thrombosis and disseminated primary JCPyV infection originating from the kidney allograft. Clinical improvement followed removal of the allograft and cessation of immunosuppression. A 27-year-old man presented to hospital with confusion and headache 9 months after receiving a kidney transplant. Medical history included diarrhea-associated hemolytic uremic syndrome as an infant, with subsequent chronic kidney disease and progression to end-stage kidney disease. He commenced peritoneal dialysis and 4 years later received a 3/6 HLA mismatch, deceased donor transplant. The donor was cytomegalovirus (CMV)-positive and Epstein-Barr Virus (EBV) IgG-positive and the patient was CMV-negative and EBV IgG-negative. Immunosuppression comprised basiliximab induction (20 mg on day 0 and day 4), mycophenolate sodium (720 mg, twice daily), tacrolimus (2 mg, twice daily), and prednisolone (8 mg daily). The posttransplantation period was uncomplicated, achieving a baseline creatinine of 1.13 mg/dL without episodes of acute rejection or treatment with T-or B-cell-depleting antibodies. Standard transplant center protocol for monitoring BK polyomavirus (BKPyV) was followed up posttransplant (plasma was monitored at 1, 2, 3, 6, 9, 12, 18, and 24 months).
The patient had a 10-day history of headache, vertigo, confusion, and intermittent right-sided weakness. On examination, he was afebrile and disoriented to time and place. The blood pressure was 112/78 mm Hg and pulse was 110 beats per minute. He had a bilateral upper limb resting tremor, reduced sensation in the right arm and leg and an ataxic gait. There were no papilledema, meningismus, rash, hepatosplenomegaly, or lymphadenopathy. Creatinine was 1.37 mg/dL; hemoglobin, 14.1 g/dL; white blood cell (WBC) count, 6 Â 10 3 /μL; and platelets, 193 Â 10 3 /μL. Trough tacrolimus level was 4.8 ng/mL. Coagulation studies were significant for a 20210G>A heterozygous prothrombin gene mutation. However, prothrombin, activated partial thromboplastin time, lupus anticoagulant, activated protein C resistance, antithrombin 3, and protein C and S studies were normal.
A brain X-ray computed tomography was normal, but magnetic resonance imaging (MRI) (including venogram) showed an acute left transverse venous sinus thrombosis ( Figure 1A ) without brain parenchymal lesions (not shown). The patient was anticoagulated with heparin and then warfarin.
An electroencephalogram showed frequent bursts and runs of higher voltage symmetrical delta activity with no epileptiform discharges, suggesting either raised intra cranial pressure or a diffuse encephalopathy. BK polyomavirus, CMV, EBV, and herpes simplex virus DNA were not detectable by polymerase chain reaction (PCR) in peripheral blood. During the following week, the delirium worsened with increasing confusion and disorientation. A computed tomography scan of the chest, abdomen, and pelvis showed no evidence of posttransplant lymphoproliferative disease. Two weeks after the initial presentation, cognition improved. Repeat MRI showed resolution of the venous cerebral thrombosis (not shown) with no parenchymal lesions or meningeal inflammation ( Figure 1B ). However, 3 weeks after admission, the delirium worsened and repeat electroencephalogram reported a frequent generalized delta activity consistent with severe diffuse encephalopathy. An alternative diagnosis was sought because this deterioration was considered inconsistent with venous sinus thrombosis. A lumbar puncture was performed, and analyses of the cerebrospinal fluid (CSF) showed an increased protein concentration of 92 mg/dL, low glucose (48.6 mg/dL), WBC of 1.3 Â 10 1 /μL (mononuclear cells, 99%; polymorphs, 1%) and red blood cell count of 9 Â 10 0 /μL. Flow cytometry, India ink, cryptococcal antigen, and Ziehl-Neelsen studies were normal; and culture for bacterial and fungal pathogens was negative.
Due to progressing symptoms, a repeat CSF examination was performed 5 days later showing the presence of JC polyomavirus (JCPyV) DNA by PCR. The CSF was PCR negative for CMV, EBV, herpes simplex virus 1 and 2, varicella-zoster virus, adenovirus, rabies, and lyssavirus. The CSF cell count could not be ascertained due to blood contamination.
The diagnosis of JCPyV-associated encephalopathy was established and the implications discussed with the patient and family. Over a period of 17 days, the mycophenolate dose was initially halved and then ceased; and the tacrolimus dose was reduced aiming for a level of 4 ng/mL; however, there was no improvement in the delirium. Retrospective quantitative PCR (qPCR) showed increasing JCPyV loads in blood starting 5 months before onset of neurological symptoms, but negative in the pretransplant serum.
Sequential collections of blood remained positive for JCPyV by qPCR ( Figure 2A ). Due to a lack of improvement in neurological symptoms and concerns of permanent cognitive impairment or death, he underwent transplant nephrectomy and cessation of immunosuppression 7 weeks after his initial presentation. Histopathology of the explanted kidney demonstrated mild tubulointerstitial scarring, moderate vascular sclerosis and microcystic change, but no evidence of rejection. Tubules and collecting ducts within the medulla occasionally showed mild nuclear abnormalities including enlargement and nuclear staining with SV40 antibody that cross-reacts with JCPyV ( Figure 3 ). No SV40 staining was evident in the renal cortex.
Once immunosuppressive therapy was ceased, the patient's delirium resolved over 2 weeks. Nine months after discharge from hospital, the patient was stable on hemodialysis, with regained baseline cognition and complaints of only occasional left arm paresthesia and mild vertigo. A CSF examination performed 9 months posttransplant nephrectomy showed normalization of protein levels to 23 mg/dL, with a WBC count of 1.2 Â 10 1 /μL (mononuclear, 97%; polymorphs, 3%) and RBC count of 3 Â 10 0 /μL. In contrast, no JCPyV was detected in the blood of the patient who received the deceased donor's contralateral kidney. However, this patient did subsequently develop BK viremia without polyomavirus-associated nephritis.
MATERIALS AND METHODS

Real-Time PCR and Genomic Analyses
DNA from blood, serum, urine, flocked nasal swabs (Copan Diagnostics, USA) and CSF (200 μL of each sample) was extracted using Roche High Pure Viral Nucleic Acid kits (Roche Diagnostics, Australia), whereas Qiagen DNeasy Blood & Tissue kits (Qiagen, Australia) were used for kidney tissue (approximately 25 mg) DNA extraction, as per manufacturer's instructions. Nasal swabs were suspended in 1 mL of phosphate buffered saline before extraction. Fresh scalpel blades and plasticware were used to collect the different sections of kidney tissue.
Endogenous retrovirus 3 1 was used for cellular quantification. Real-time PCRs specific for BKPyV (assay V3A) 2 and JCPyV (assay JL1) 3 were used for both initial diagnostic testing and subsequent quantification. Primer targets did not share homology with any of the newly discovered human polyomaviruses. Quantified A549 tissue culture and a 3373 bp pMA-RQ (ampR) synthetic plasmid containing the JL1 assay target (Life Technologies, Germany) were used to generate standard curves for quantification of endogenous retrovirus 3 and JCPyV, respectively.
JC polyomavirus genomes were generated using PCR with 10 overlapping primer pairs (see Table S1 , SDC, http://links.lww.com/TP/B285) and standard Sanger sequencing. Genome assembly and analyses were performed using CLC Main Workbench 6.6.1 (CLC Bio, Denmark).
Immunohistochemistry
After nephrectomy, one third of the graft was fixed for further histopathological investigations. Immunohistochemical detection of JCPyV was performed using a monoclonal mouse antibody against the large T antigen (LTAg) of SV40, which also cross-reacts with JCPyV's LTAg (Calbiochem, catalogue no DP02, at a 1:200 dilution). Sections were cut onto coated slides, and automated immunoperoxidase staining was performed using the Ventana Benchmark Ultra (Ventana Medical Systems, USA). This method included heat retrieval at pH 8 and the Optiview detection system (Roche Diagnostics, USA).
JCPyV and BKPyV Serology
JC polyomavirus and BKPyV serology was conducted as previously described, 4 apart from JCPyV proteins being substituted for BKPyV. Briefly, JCPyV and BKPyV VP1 capsid proteins were generated using a baculovirus expression system, with the resulting self-assembled virus-like particles being used as antigens in microtitre plate-based ELISAs. Serum was used at a 1:100 dilution.
RESULTS
Virus Detection and Quantification
Blood viral loads gradually increased and were extremely high in CSF, serum, and urine during the peak of the patient's neurological symptoms, in addition to JCPyV detection in the upper respiratory tract (Figures 2A, B) .
JC polyomavirus loads were highest in the medulla of the kidney explant (23.6 copies/cell), followed by the minor calyx (2.71 copies/cell), renal pelvis (1.64 copies/cell), and cortex (0.57 copies/cell). BK polyomavirus was not detected in any sample.
Subsequent to cessation of immunosuppression, viral loads in serum gradually decreased by 5 logs, although 9 months later, JCPyV continued to be detected at low levels in serum and CSF (Figures 2A, B) .
Genetic Analyses
Six full-length JCPyV genomes were sequenced from a range of samples collected throughout the study period (Figure 2A) , as well as from the medulla section of the explant. All 7 genomes were identical. The virus' noncoding control region (NCCR) was identical to that of healthy archetype JCPyV isolate CY (AB038249) and did not contain any mutations in the Agnoprotein or viral protein 1 genes previously associated with progressive multifocal leukoencephalopathy (PML) or other neurological diseases. [5] [6] [7] [8] [9] [10] Examination of the relevant sequencing chromatograms did not reveal evidence of minor JCPyV populations harbouring genomic mutations. Attempts to sequence the final CSF were not successful. The sequenced genome was deposited as isolate QLD-01 (Accession number HG764413).
Serology
The patient was JCPyV seronegative pretransplant up until the commencement of neurological symptoms, when serum viral loads peaked. IgG titres thereafter rapidly rose, correlating with decreasing viral loads and IgM titres ( Figure 2B) . Likewise, the contralateral KTR recipient was also JCPyV naïve pretransplantation, in contrast to the donor's seropositivity for JCPyV (see Table S2 , SDC, http://links.lww.com/TP/B285). Both recipient and the donor sera were seropositive for BKPyV however, the case patient's pretransplantation seroreactivity was substantially lower (see Table S2 , SDC, http://links.lww.com/TP/B285).
DISCUSSION
After primary infection, JCPyV latency is established within the kidney, although other sites have also been described. JC polyomavirus reactivates under immunosuppressive conditions causing varied neurological diseases including PML, 10 granule cell neuronopathy, 7 meningitis, 13 and JCPYV encephalopathy.
14 In kidney transplant recipients (KTRs), JCPyV reactivation is not uncommon; however, JCPyVassociated neurological events are rare. 15 JC polyomavirus involvement in our patient was not considered at the time of initial presentation due to the MRI finding of cerebral venous sinus thrombosis, but was diagnosed after progression of the patient's delirium. The increasing JCPyV viral loads in blood, high JCPyV viral load in CSF, and progressive neurological deterioration suggested JCPyV cerebral involvement. A previous review of PML outcomes in 9 KTRs reported 7 deaths and residual neurological damage in 2 survivors. 16 Given the high risk of permanent neurological sequelae or death in other JCPyV-associated neurological diseases, 16 immunosuppression was ceased, and the patient underwent a transplant nephrectomy with the aim of immune reconstitution and control of the viral infection. Although nephrectomy resulted in the patient's return to dialysis; there were significant reductions in blood and CSF viral loads, and a resolution of delirium and neurological symptoms occurred. Interestingly, our patient continued to shed JCPyV in his CSF without the presence of significant neurological symptoms which has not been previously described. Two years posttransplant nephrectomy, the patient remains stable on hemodialysis with only mild neurological symptoms consisting of occasional arm paresthesia and vertigo.
The JCPyV NCCR and the major viral capsid protein VP1 are key determinants of the virus' tissue tropism. 8, 9, 12 Rearrangements in JCPyV's NCCR arise from unchecked replication after immunosuppression, and along with mutations in VP1 and the JCPyV agnoprotein, have been associated with the development of various neurological diseases. 6, 7, 10, 13 In this case, however, the virus remained genetically stable over 8 months, although it was not possible to address the presence of mutant JCPyV species in localized cerebral areas, as described previously. 6 Although the presence of JCPYV variant subpopulations in the CSF cannot be completely excluded, the lack of minor peak signals in the sequencing data suggests that the dominant strain within the CSF is indeed archetype, rather than being a manifestation of blood contamination. JC polyomavirus NCCR alterations occur frequently during immunosuppression within both the CNS and blood 17 ; however, CSF-originating archetype JCPyV within the setting of neurological disease is not an unprecedented, albeit rare, occurrence. 18 Thus, these findings suggest that archetype JCPyV is capable of infecting the CNS, a proposition which is further reinforced by Sock et al 19 report of archetype NCCR's capacity for activity within glial cells, although at a lower level to that of rearranged NCCR variants.
Neurological symptoms were not consistent with dural sinus thrombosis which in conjunction with the worsening symptoms despite the radiological resolution of the thrombus, point to an alternate etiology. The development of posterior reversible encephalopathy syndrome can be linked to acute increases in blood pressure and use of immunosuppressive agents, and describes a clinical syndrome of headache, visual disturbance, confusion, decreased level of consciousness, and seizures which are associated with characteristic radiological findings of posterior cerebral white matter edema. 20 Although posterior reversible encephalopathy syndrome is an important differential diagnosis and was considered, it was thought unlikely because both the patient's blood pressure and tacrolimus dosing were stable, along with the absence of any neuroimaging abnormalities within the brain parenchyma on any of the 3 MRI scans performed (sagittal T1, coronal T2, axial fluid attenuated inversion recovery, diffusion weighted imaging, apparent diffusion coefficient, T1, susceptibility weighted imaging sequences of the brain, magnetic resonance venography and 3-dimensional time of flight magnetic resonance angiography axial, coronal and sagittal T1 magnetizationprepared rapid gradient echo postgadolinium sequences). The use of mycophenolate has been widely associated with JCPyV replication, which we found to peak concurrently with neurological symptoms. Cessation of mycophenolate restored the humoral response and led to a reduction in viral replication and symptoms. The multiple lines of evidence and the timing of events therefore suggest JCPyV as the primary etiological agent of pathogenesis in this case. Although the neurological presentation was similar to that of previously described JCPyV encephalopathy, 14 the presence of archetype JCPyV genome, cerebral venous sinus thrombosis, and a lack of typical radiological lesions led us to consider this a novel case of atypical JCPyVassociated encephalitis.
The high viral loads found in the blood and urine represents a poorly regulated systemic JCPyV infection, highlighted by JCPyV's unexpected detection within the nasal cavity. The respiratory tract has long been suspected of being a potential route of JCPyV transmission; however, the presence of the virus in airways has not been previously described. The JCPyV detection in the respiratory swab may represent a rare occurrence of JCPyV replication within the respiratory tract, or alternatively, may purely be due to a spillover event from high viral loads circulating within the blood. Of note, the initial CSF was contaminated with blood during collection, which indicates that the actual CSF JCPyV load may have been lower than calculated; however, we consider the virus presence as genuine, as 9 months later, JCPyV continued to be detected within the blood-free CSF. This observation also reinforces the need to take sample quality into consideration when assessing diagnostic CSF results. Viral loads were dramatically higher in the medulla of the kidney compared with other explant sections, which, together with strong LTAg protein staining within the collecting duct cells of the medulla points to an active localized infection within the kidney graft. The infrequent nuclear staining patterns observed in this case are a consistent feature found in previous reports of JCPyV nephropathy, [21] [22] [23] although the lack of graft dysfunction or evidence of acute rejection has been recorded less frequently. 21 The observed seronegativity pretransplant, a robust rise and fall of the IgM response, and the seroconversion and rise in the IgG titer, concurrent with the decreasing serum viral loads demonstrate all the hallmarks of a primary infection. The serological data from the case report patient and donor, in concert with the archetype JCPyV replication in the graft and identical circulating genomes throughout the body point to an unchecked primary infection seeded by a JCPyV-positive graft.
An interfering BKPyV effect has been proposed by Cheng and colleagues, 24 whereby a high humoral response to BKPyV was observed to have a protective effect against JCPyV viruria in the KTR population. The observed protective effect may be due to cross-reactive antibodies, or more likely, from a parallel cross-reactive cellular immunity response as proposed by Rossi et al. 25 The role of the humoral response in regulating polyomavirus infection is still not well understood; however, it appears to increase with rising polyomavirus replication levels. 26 In contrast, the T cell response has been shown to not only regulate the polyomavirus infections, but to also be capable of cross-protection between BKPyV and JCPyV. 27 In the absence of a sufficient T cell response, high titres of antibodies may be sufficient to clear the virus from the blood. 27 Despite both KTRs sharing a JCPyV-positive donor and both seropositive for BKPyV pretransplant, only the case report patient went on to develop JCPyV infection. Unlike the contralateral patient, however, the case report patient had much lower seroreactivity to BKPyV; thus, the combination of JCPyV naivety and a low BKPyV humoral response may have been sufficient to lead to a donorderived uncontrolled JCPyV infection. In contrast, the higher BKPyV seroresponse in the contralateral KTR may have been sufficient enough to offer cross-protection to either prevent or regulate the JCPyV infection to subclinical levels.
This case, along with a recent report of JCPyV-associated nephritis, 23 highlights the potential of JCPyV to cause severe disease in naïve patients after kidney transplantation and argues for the value of including JCPyV screening in patients with graft dysfunction or neurological disease.
JC polyomavirus is capable of binding and aggregating type-O erythrocytes, and this mechanism is the basis of proposed increased PML risk among patients with type-O blood. 28 Indeed, the current case's blood type was type O, which suggests that high virion loads in conjunction with the prothrombin gene mutation 29 created the environment for virus-mediated hemagglutination, and consequently, venous sinus thrombus development. Additionally, elevated CSF WBC and protein counts suggested the presence of meningeal inflammation, which could also have contributed to the development of the thrombus, as the 2 are known to be associated. 30 The thrombus may have then facilitated the release of JCPyV into CSF by reverse flow through arachnoid villae and possible infection of the choroid plexus, resulting in the observed persistent JCPyV presence in the CSF and lack of cerebral lesions. This is a unique case of atypical JCPyV-associated encephalopathy presenting with disseminated primary JCPyV infection, cerebral venous sinus thrombosis, and a lack of typical brain lesions on MRI scans. The demonstration of JCPyV in blood, CSF, the LTAg staining in the renal collecting duct cells, the robust serological response, coupled with the neurological presentation, and improvement of the patient following graft nephrectomy and cessation of immunosuppression suggests JCPyV to be the causative agent in this case. It is also notable that the viral genome isolated from the blood and CSF was not of the usual neuroinvasive type. These findings emphasize the importance of comprehensive CSF examination in immunosuppressed patients with delirium.
